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Background
Schizophrenia affects 1% of the population. Clozapine is the only
medication licensed for treatment-resistant schizophrenia and is
intensively monitored to prevent harm from neutropenia.
Clozapine is also associated with increased risk of pneumonia
although the mechanism is poorly understood.
Aims
To investigate the potential association between clozapine and
antibody deficiency.
Methods
Patients taking clozapine and patients whowere clozapine-naive
and receiving alternative antipsychotics were recruited and
completed a lifestyle, medication and infection-burden ques-
tionnaire. Serum total immunoglobulins (immunoglobulin (Ig)G,
IgA, IgM) and specific IgG antibodies to haemophilus influenzae
type B, tetanus and IgG, IgA and IgM to pneumococcus were
measured.
Results
Immunoglobulins were all significantly reduced in the clozapine-
treated group (n = 123) comparedwith the clozapine-naive group
(n = 111). Odds ratios (ORs) for a reduction in clozapine:control
immunoglobulin values below the fifth percentile were IgG, OR =
6.00 (95% CI 1.31–27.44); IgA, OR = 16.75 (95% CI 2.18–128.60);
and IgM, OR = 3.26 (95% CI 1.75–6.08). These findings remained
significant despite exclusion of other potential causes of hypo-
gammaglobulinaemia. In addition, duration on clozapine was
associated with decline in IgG. A higher proportion of the cloza-
pine-treated group reported taking more than five courses of
antibiotics in the preceding year (5.3% (n = 5) versus 1% (n = 1).
Conclusions
Clozapine use was associated with significantly reduced
immunoglobulin levels and an increased proportion of patients
using more than five antibiotic courses in a year. Antibody
testing is not included in existing clozapine monitoring pro-
grammes but may represent a mechanistic explanation and
modifiable risk factor for the increased rates of pneumonia
and sepsis-related mortality previously reported in this
vulnerable cohort.
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Schizophrenia affects around 1% of the population and approxi-
mately 30% of patients have treatment-resistant schizophrenia for
which clozapine is the only licensed medication. In addition to
debilitating psychiatric symptoms it is associated with an
unemployment rate of 80–90% and a life expectancy reduced by
10–20 years.1 Approximately 5% of those diagnosed with schizo-
phrenia die by suicide.2 Although clozapine reduces overall mortal-
ity in severe schizophrenia,3 it is associated with a number of often
poorly understood side-effects with a growing body of evidence
linking clozapine with elevated rates of pneumonia-related admis-
sion and mortality.4–9 Mortality from respiratory infections/sepsis
despite intensive monitoring is a common reason for discontinuing
treatment.10,11 Various mechanisms for the increase in pneumonia
have been suggested, including aspiration, sialorrhoea and impair-
ment of swallowing function with oesophageal dilatation and hypo-
motility as well as agranulocytosis12 and smoking.13 The possibility
of a link between antibody deficiency and clozapine use was first
raised during a study of population screening for antibody defi-
ciency using calculated globulin screening in Wales.14 Calculated
globulin is derived from the difference between total serum
protein and albumin concentrations, part of the liver function test
profile. Immunoglobulins form a significant proportion of the
globulin fraction and therefore low calculated globulin may indicate
antibody deficiency.14,15 Antibody deficiency is not a listed clozapine
side-effect and is not a part of current clozapine monitoring. To
further assess a possible association between antibody deficiency
and clozapine use we undertook a cross-sectional case–control study
to compare the immunoglobulin levels and specific antibody levels
in patients taking either clozapine or alternative antipsychotics.
Method
Participants
Adults (>18 years) receiving either clozapine or non-clozapine anti-
psychotics were recruited during routine clinic visits to ten commu-
nity mental health team out-patient clinics in Cardiff & Vale and
Cwm Taf Health Boards by specialist research officers between
November 2013 and December 2016. All potential participants
were given the same participant information leaflet to read that out-
lined the purpose of the study and indicated that they would be
asked some questions about their health and have a single (4 mL)
blood sample taken. Following consent, participants completed
the short lifestyle, drug history and infection questionnaire followed
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by blood sampling. Where required, drug histories were confirmed
with the patient’s general practice records. Formal psychiatric diag-
noses and antipsychotic medication use were confirmed using the
medical notes, in line with other studies. Patients’ admission rates
were confirmed by electronic review for all patients in the post-
exclusion group over the 12-month period prior to recruitment
and assessed for an infective trigger.
Measurements
Immunoglobulin levels (immunoglobulin (Ig)G, IgA and IgM) were
assayed by nephelometry (Siemens BN2 Nephelometer; Siemens),
serum electrophoresis (Sebia Capillarys 2; Sebia, Norcross, GA,
USA) and, where appropriate, serum immunofixation (Sebia
Hydrasys; Sebia, Norcross, GA, USA). Where immunoglobulin
was detectable, the lower limit of assay sensitivity (IgG, 1.34 g/L;
IgA, 0.24 g/L; and IgM, 0.17 g/L) was used for data analysis.
Specific antibody titres against haemophilus influenzae, tetanus
and pneumococcal capsular polysaccharide were determined
by enzyme-linked immunosorbent assay (The Binding Site,
Birmingham, UK). All testing was performed in the United
Kingdom Accreditation Service accredited Immunology Laboratory
at the University Hospital of Wales. Laboratory adult reference
ranges for immunoglobulin levels used were, IgG, 6.00–16.00 g/L;
IgA, 0.80–4.00 g/L; IgM 0.50–2.00 g/L.
Statistical analysis
Statistical analysis of the laboratory and clinical data was performed
using Microsoft Excel and Graphpad Prism (version 6.07).
Unadjusted odds ratio (ORs) and 95% confidence intervals were
calculated using Fisher’s exact test for the number of individuals
with an immunoglobulin value below the lower limit of normal
(IgG <6.00 g/L, IgA <0.80 g/L and IgM <0.50 g/L). As the distribu-
tion of all three immunoglobulin classes in the study population
differed from a Gaussian distribution (Fig. 1), non-parametric
Mann–Whitney U-testing was performed. Specific antibody titres,
antibiotics and admission frequencies were similarly evaluated.
No validated protective values are currently available for pneumo-
coccal-specific IgA or IgM as a relevant threshold, and odds ratios
were not calculated.
To adjust for factors, other than clozapine treatment (age,
gender, diabetes, asthma/chronic obstructive pulmonary disease
(COPD), second antipsychotic, diagnosis of schizophrenia and dur-
ation of clozapine therapy) that might influence immunoglobulin
levels, linear regression analysis was performed in R (version
3.4.0). These models included a term corresponding to a global
difference in levels between the two groups and, by way of an inter-
action with treatment duration, a term corresponding to a reduction
in immunoglobulin levels per year on clozapine or other
antipsychotic.
The study received ethical approval from theNorthWest Regional
REC committee (REC Reference 13/EM/0209, IRAS ID 104402) and
sponsorship from Cardiff & Vale University Health Board.
Results
Study participants
A total of 291 patients taking clozapine and 280 who were clozapine
naive were approached and 123 taking clozapine and 113 who were
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Fig. 1 Immunoglobulin levels in the clozapine-treated and clozapine-naive groups.
The distribution of the serum levels of immunoglobulin (Ig)G, IgA and IgM for the clozapine-treated (light blue, n = 94) and clozapine-naive (dark
blue, n = 98) groups are shown with the laboratory 5th and 95th percentile of the reference ranges for a healthy adult population represented as
vertical dotted lines. The differences between the median IgG, IgA and IgM levels for the clozapine-treated versus clozapine-naive groups are all
significant (P < 0.0001).
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clozapine naive consented to the study (Table 1). Recruitment was
stopped as per protocol when more than 100 patients in each
group had been achieved. There were small differences in gender
with more men in the clozapine-treated group (53% versus 50%)
and a lower mean age in the clozapine group (45 versus 50 years).
These differences may reflect themale predominance in schizophre-
nia and is unlikely to be relevant as there are no gender or age dif-
ferences in the adult reference range for serum immunoglobulins.16
In the post-exclusion cohort, the levels of smoking, diabetes,
COPD/asthma, and alcohol intake were similar between the
groups (Table 2). As expected almost all (94%, n = 88) of the
patients taking clozapine were diagnosed with schizophrenia or
schizoaffective disorder whereas these diagnoses accounted for
64% (n = 63) of those taking other antipsychotic medication in
the control group. This reflects the more restricted prescribing
indications for clozapine compared with other antipsychotics.
Exclusion of possible confounding medications and
diagnoses
Review of medical records in relation to the European Society of
Immunodeficiencies differential diagnosis of hypogammaglobuli-
naemia17 highlighted a number of patients with possible drug or
infection-related contributors; including anti-epileptic or mood sta-
bilising medications, previous chemotherapy, presence of parapro-
tein, or HIV infection who were excluded from the analysis
(Table 1).
Median concentrations of serum immunoglobulins for both
pre- and post-exclusion patient cohorts receiving clozapine are
shown in Table 3. Patients receiving clozapine showed significantly
reduced median concentrations of all three immunoglobulin classes
(IgG, IgA and IgM) relative to the clozapine-naive control group.
The relative shift in distributions is highlighted in Fig. 1 (post-exclu-
sion groups represented).
The odds ratios for individual patients having an immuno-
globulin measured below the lower limit of the reference range
are also shown in Table 3. In the post-exclusion groups, 1%
(n = 1) of controls and 8.5% (n = 8) of clozapine-treated group
had IgG levels <6.00 g/L; 13.8% (n = 13) of clozapine and no con-
trols had IgA levels <0.80 g/L; and 34% (n = 32) of clozapine and
15.3% (n = 15) of controls had IgM levels <0.50 g/L. Furthermore,
three patients in the clozapine group had evidence of reduction of
all three immunoglobulin classes; two patients had severely
reduced IgG below 4.00 g/L. The lowest IgG in the clozapine
group was 2.59 g/L, compared with 5.92 g/L in the control group.
These differences were statistically highly significant (P < 0.017 or
below) despite reduction in sample size, with exclusion of three clo-
zapine-treated individuals with IgG values of 3.19, 4.93 and 5.42 g/L
(taking concurrent anti-epileptic medications). One patient with an
IgG of 5.79 g/L was similarly excluded from the control group. All
subsequent analysis of results has been undertaken on the cohort
following exclusion of possible confounding medications and
diagnoses.
Specific antibody levels are low in both clozapine-
treated and clozapine-naive groups
Large percentages of individuals in both the clozapine-treated and
clozapine-naive groups have specific IgG antibody levels below
the protective levels for haemophilus influenzae B (51.1% (n = 48)
and 54.1% (n = 53) less than 1 mcg/mL, respectively),24 pneumo-
coccus (52.1% (n = 49) and 54.1% (n = 53) less than 50 mg/L,
respectively)18 and tetanus (10.6% (n = 10) and 13.3% (n = 13)
less than 0.1 IU/mL, respectively). These were not significantly
different using non-parametric testing. In contrast, levels in the
clozapine-treated group for pneumococcal-specific IgA were
reduced by 28 IU/mL over the clozapine-naive group (30.8 U/mL
versus 58.8 U/mL P < 0.001) and IgM was reduced by 26 IU/mL
(59.8 U/mL versus 85.8 U/mL P < 0.001) perhaps reflecting the
observed greater relative reductions in total IgA and IgM levels
(supplementary Table 1 available at https://doi.org/10.1192/bjp.
2018.152). It should be noted that although values for protective
levels of specific antibodies of haemophilus influenza B (>1 mcg/mL)
and tetanus (>0.1 IU/mL) are reasonably well-validated there remains
ongoing debate regarding the protective levels of pneumococcal
antibodies.
Longer duration of clozapine use is associated with
increased risk of hypogammaglobulinaemia
Information on duration of antipsychotic use was available for 88 of
the 94 individuals in the clozapine group and 97 of 98 of those in the
Table 1 Study participants and excluded participants
Clozapine
group Control group
Total screened, n 291 280
Declined/unable to consent or provide
serum, n
168 169
Initial cohort, n 123 113
Excluded from subsequent analysis,a n 29 15
Carbamazepine 2 1
Lamotrigine 5 5
Levetiracetam 1 –
Topiramate 1 –
Valproate 17 5
Paraprotein 1 3
Leflunomide – 1
Prior chemotherapy 1 –
HIV 1 –
Post-exclusion cohort, n (% of total
screened)
94 (32.3) 98 (35.0)
a. Included in initial cohort analysis for total and specific antibody levels and excluded
from subsequent analysis after identification of possible causes of secondary hypo-
gammaglobulinaemia (European Society of Immunodeficiencies criteria).
Table 2 Participant characteristics of the post-exclusion cohort
Clozapine group
(n = 94)
Control group
(n = 98)
Age, years: mean (range) 44.4 (22.0–78.0) 50.4 (21.6–78.0)
Gender, men:women 64:30 54:44
Dual antipsychotic treatment, n (%) 29 (30.9) 11 (11.2)
Duration of antipsychotic use, years:
median (range)
8 (0.1–20) 7 (0.1–44)
Current smoking, n (%) 57 (60.6) 55 (56.1)
Diabetes, n (%) 19 (20.2) 16 (16.3)
Chronic obstructive pulmonary
disorder/asthma, n (%)
12 (12.7) 16 (16.3)
Alcohol intake, units per week: mean
(range)
5.3 (0–60) 6.0 (0–68)
Primary psychiatric diagnosis, n
Schizophrenia 87 58
Schizoaffective disorder 1 5
Bipolar 0 11
Psychosis 0 15
Depression 0 3
Personality disorder 2 2
Anxiety disorder 0 2
Electronic record incomplete 4 2
Antibiotic courses in 12 months, n (%)
No courses 57 (60.6) 62 (63.3)
1–5 courses 32 (34.0) 35 (35.7)
>5 courses 5 (5.3) 1 (1.0)
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clozapine-naive group (post-exclusion cohort) and shows a decline
in serum IgG levels only in those receiving clozapine (Fig. 2).
To adjust for possible confounding variables that differed
between groups (age, gender, diabetes, asthma/COPD, use of a
second antipsychotic and diagnosis of schizophrenia) we performed
linear regression analysis. Self-reported variables including current
cigarette and alcohol consumption were similar between groups,
although information on daily consumption was variably completed
and considered vulnerable to reporting bias and were therefore not
included. Medically documented diagnoses of asthma/COPD or
diabetes were included as variables, as these conditions might theor-
etically be associated with use of immunosuppressive medication
such as glucocorticoids not documented in available electronic
general practitioner or psychiatric medical records.
Despite adjustment, there remained statistically significant
immediate decreases in IgA (0.57 g/L, P = 0.01) and IgM (0.32 g/L,
P = 0.02) and a significant association between decline in IgG and
clozapine duration (P = 0.03), with a fall of serum IgG by 0.15 g/L
per year (supplementary Table 2). Serum IgA and IgM did not
show a significant correlation with duration of antipsychotic use,
potentially as a result of an earlier effect and that the lower limit
of the reference range for IgA (0.8 g/L) and IgM (0.5 g/L) is closer
to the sensitivity of nephelometric testing at <0.24 g/L for IgA and
<0.17 g/L for IgM. Serum IgM decreased with age in both groups
(not shown).
Using this model, we were also able to estimate the impact of
clozapine duration on serum IgG levels following clozapine or
non-clozapine antipsychotic medication use for an average 40-
year-old male, shown in supplementary Table 3 over a period of
25 years.
Antibiotic usage and admission rates for infection
Accepting the inherent shortcomings of self-reported data and the
small number of reported events for the secondary outcomes of
antibiotic usage and hospital admissions over the previous 12
months, the clozapine-treated group had higher antibiotic use,
with a greater percentage of patients reporting more than five
courses of antibiotics per year 5.3% (n = 5) versus 1% (n = 1) in
Table 3 Immunoglobulin concentrations and odds ratio for the
clozapine-treated and clozapine-naive groupsa
Clozapine
group
Control
group P
Pre-exclusion cohort, n 123 113
IgG, median 9.31 10.6 <0.0001b
IgA, median 1.58 2.46 <0.0001b
IgM, median 0.61 0.91 <0.0001b
Post-exclusion cohort, n 94 98
IgG, median 9.21 10.6 <0.0001b
IgA, median 1.55 2.46 <0.0001b
IgM, median 0.64 0.91 <0.0001b
Pre-exclusion cohort OR (95% CI)
IgG <6.0 g/L 6.00 1.31–27.44 0.0120c
IgA <0.8 g/L 16.75 2.18–128.6 0.0002c
IgM <0.5 g/L 3.26 1.75–6.08 0.0001c
Post-exclusion cohort OR (95% CI)
IgG <6.0 g/L 9.02 1.11–73.65 0.0168c
IgA <0.8 g/L 32.63 1.91–558 <0.0001c
IgM <0.5 g/L 2.86 1.42–5.73 0.0040c
a. Values represent median serum immunoglobulin concentrations in g/L. Reference
range for 5th to 95th centiles in healthy adults: IgG, 6.0–16 g/L; IgA, 0.8–4.0 g/L; IgM,
0.5–2.0 g/L.
b. Mann–Whitney test.
c. Fisher’s exact test.
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Fig. 2 Effect of duration of antipsychotic (upper) or clozapine (lower) treatment on immunoglobulin (Ig)G levels.
A significant negative correlation of duration of clozapine use (years) was observed with an annual reduction in IgG levels of 0.15 g/L (P = 0.03).
No correlation was seen with serum IgG level and non-clozapine antipsychotic medications (P = 0.14) despite a longer duration on therapy.
Straight lines show predicted IgG at different durations of treatment (in years), based on fitted linear models. Shaded regions display pointwise
95% confidence intervals.
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the control group (Table 2). It was possible to validate hospital
admissions by checking electronic medical records, thus reducing
recall bias and allowing assessment of the admission trigger.
There was a trend towards greater rate of confirmed infection-
related admissions per patient year in the clozapine-treated group
over the control group (8 versus 6, respectively; equating to 0.08
versus 0.06 per patient year); however, this was not statistically sig-
nificant. On an individual patient basis, these admissions clustered
in four patients taking clozapine and occurred in six control
patients.
Discussion
Clozapine is a dibenzo-diazepine atypical antipsychotic, and since
1990 the only licensed therapy in the UK for the 30% of patients
with treatment-resistant schizophrenia. It shows superior efficacy
in patients with schizophrenia and is effective in approximately
60% of those patients who were previously treatment refractive
with a significant reduction in suicide risk.1,19 The National
Institute for Health and Care Excellence guideline recommends
that adults with schizophrenia that have not responded adequately
to treatment with at least two antipsychotic drugs should be offered
clozapine; however, evidence shows it to be underprescribed.1,20
In this study, we found that taking clozapine is associated with a
significant and substantial reduction in serum immunoglobulins.
Even following exclusion of other recognised potential causes of
antibody deficiency, clozapine therapy was associated with
IgG <6.0 g/L in 8.5%, IgA <0.8 g/L in 13.8% and IgM <0.5 g/L in
34% of the 94 patients. The magnitude of the reduction in immuno-
globulins is considerable when compared with the percentages of
patients with secondary antibody deficiency following long-term
combination therapy with rituximab (a monoclonal antibody tar-
geting B cells) and methotrexate for rheumatoid arthritis based on
pooled data from the rituximab clinical trials programme: IgG <
6 g/L in 3.5%, IgA <0.8 g/L in 1.1% and IgM <0.5 g/L in 22.4%.21
Our linear regression model suggests a lower initial IgG concentra-
tion (‘lower reserve’) is associated with an earlier approach to the
lower limit of the reference range, which is in keeping with
known risk factors for secondary antibody deficiency following
immunosuppressive therapies such as steroids and rituximab.22 In
general, the greater the fall in IgG level below the lower limit of
the reference range, the greater the probability of infections. Early
diagnosis of antibody deficiency enables prevention of chronic
infection, sepsis, end organ damage and death.23
Strengths and limitations of this study
Limitations of this work include the lack of prospective data, dur-
ation of follow-up and study size. In addition, there are shortcom-
ings inherent in self-reported data and research officers
administered the questionnaire and thus were not masked to par-
ticipant medications. The width of confidence intervals presented
alongside odds ratios reflect the relatively small sample size and
low numbers of patients with values below the threshold for IgG,
IgA or IgM used in both groups. Despite this, a higher proportion
of patients needing more than five antibiotic courses in 12
months was seen in the clozapine recipients within this study, in
keeping with previously reported increased antibiotic use.
Despite these limitations, all odds ratios were above one for total
immunoglobulin classes and were highly statistically significant.
These findings remained despite rigorous exclusion of patients
with known possible causes of antibody deficiency.17 This is a
strength and limitation of this study. Our aim was to reduce
potential bias, however, the evidence for associations between
medications such as carbamazepine or valproate and hypogamma-
globulinaemia are largely based upon case reports. Exclusion of
these patients may therefore result in an underestimate of the true
effect size, particularly if drug interactions can contribute to
immunoglobulin deficiency. Given a potential effect of smoking
on IgG levels,24 we assessed self-reported current smoking status.
This represents a subjective measure of smoking frequency,
however, prevalence was high, similar between groups (61%
versus 56%), and in keeping with that reported elsewhere.25 It is
notable that the significant association between duration of anti-
psychotic treatment and reduction in IgG was not observed in the
clozapine-naive group, despite a longer duration of exposure to
other antipsychotic agents and was not accounted for by other
factors such as age, gender, diabetes, diagnosis of asthma/COPD,
use of second antipsychotic agent, or psychiatric diagnosis in
linear regression modelling.
A number of serious adverse effects including seizures, intes-
tinal obstruction, diabetes, thromboembolism, cardiomyopathy
and sudden cardiac death have been described with clozapine. It
has been postulated that some of these side-effects may relate to
its immunomodulatory effects,26 including agranulocytosis (cumu-
lative incidence 0.8%).27 An association of clozapine with selective
IgM deficiency has previously been suggested28 identifying isolated
IgM deficiency in six (18%) clozapine users and two controls (3%).
Differences in study size, treatment duration, and the differential
effect on immunoglobulin classes (IgM > IgA > IgG) might have
contributed to the identification of the greater risks posed by reduc-
tions in all three immunoglobulin classes reported here.
An additional strength of our study was detailed immunological
assessment of vaccine-specific responses, which are integral compo-
nents of patient evaluation and risk stratification during assessment
of humoral immunodeficiency.29 The majority of patients in both
the clozapine and control groups had baseline specific antibody
levels below the protective range for pneumococcus and haemophi-
lus, common respiratory tract pathogens. This is in contrast to the
majority of patients still having immunoglobulin levels within the
reference range (albeit significantly lower than controls for all
three classes) and likely reflects similarities between the groups in
terms of the combination of prior vaccination history and natural
exposure to these pathogens. This suggests that the population as
a whole might benefit from improved access to vaccination, particu-
larly given the numerous additional risk factors (smoking, diabetes,
alcohol intake, illicit drug use, poor diet and physical inactivity) they
may encounter.
The clozapine-treated group differed significantly from controls
with lower levels of IgA and IgM pneumococcal antibodies. IgA is
involved in defence against infection at mucosal surfaces such as
the upper and lower respiratory tract and gut. The reasons why
IgA and IgM pneumococcal antibodies were lower in the cloza-
pine-treated group is not entirely clear but may reflect the greater
relative and more immediate reductions in total IgA and IgM com-
pared with IgG relative to the healthy adult and control group range.
Implications
This work, if confirmed, has potential implications for monitoring
and risk mitigation strategies surrounding use of this important
medication. This is particularly relevant given recent changes to
the United States Clozapine Risk Evaluation and Mitigation
Strategy programme (www.clozapinerems.com) that includes low-
ering the absolute neutrophil count threshold at which interruption
of clozapine treatment is required. The impact of these changes will
allow greater flexibility in patient-specific decisions about continu-
ing or resuming treatment in patients who develop moderate to
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severe neutropenia, and so increase access to clozapine in patients
across the USA.
Further studies are urgently required to validate these findings
of immunoglobulin deficiency in a wider population of patients
receiving clozapine, and to address questions relating to causality.
These should be sufficiently powered to assess the impact of cloza-
pine dose and duration, and explore additional risk factors such as
concomitant medication, dual antipsychotic use, initial pre-cloza-
pine immunoglobulin levels, smoking levels, durability of vaccine
responses and any impact of schizophrenia itself. If confirmed
there are also potential implications for practice, as current moni-
toring schemes do not include immunoglobulin testing. Given
routine neutrophil monitoring and the centralised-nature of regis-
tries, integration of immunoglobulin and specific antibody level
testing would be relatively straightforward. This would allow iden-
tification, risk stratification and monitoring of changes over time
with individualised intervention where needed.
The association between duration of clozapine use and reduc-
tion in IgG suggests that long-term monitoring may be needed. In
addition, the results highlight the wider issue of protecting this vul-
nerable patient group from infection, irrespective of clozapine treat-
ment, by optimising vaccination status. This could be improved by
formally defining this population as a risk group (as is the case for
pneumococcal vaccination for patients with chronic lung disease,
chronic heart disease, splenectomy and diabetes) to ensure equitable
and appropriate access to protection via vaccination.
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